SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?


To: Karuna1 who wrote (49585)1/22/2019 1:33:15 PM
From: KeeptheFaith2 Recommendations

Recommended By
bobbseytwins2001
kdd999

  Respond to of 63310
 
<<Didn’t Daiichi Sankyo reported results from their study which works similar to IMMU 132? It is getting scarier.>>

Per the DS website, they do not list this in late stage development but rather in their pipeline. More specific:

DS-1062 (Anti-Trop-2 ADC) is being tested for NSCLC target in Japan and the US. It is in Phase 1.

-KTF



To: Karuna1 who wrote (49585)1/22/2019 4:12:26 PM
From: ladyPI2 Recommendations

Recommended By
bobbseytwins2001
Planeteer

  Respond to of 63310
 
go to their web - look at their pipeline.